Home > Dermatology > SPIN 2022 > Psoriasis: The Beat Goes On > Systemic treatment for psoriasis: what is on the horizon?

Systemic treatment for psoriasis: what is on the horizon?

Presented By
Prof. Diamant Thaci , University of Lübeck, Germany
Conference
SPIN 2022
Doi
https://doi.org/10.55788/22b41947
Many treatment possibilities are already available for psoriasis, but there is even more to come. A promising novel oral therapy is in the pipeline with TYK2 inhibition, which showed impressive response maintenance in a withdrawal analysis. As Prof. Diamant Thaci (University of Lübeck, Germany) pointed out, previously, researchers focused more on pathogenesis, whereas in the future, the phenotype of the patients is expected to play an important role [1]. It is crucial to recognise generalised pustular psoriasis (GPP), a rare type of psoriasis. Frequently it presents with flares of widespread sterile pustules on a background of red and tender skin. IL-36 plays a key role in the pathogenesis of the disease. Published phase 2 data of spesolimab, an anti-IL-36 receptor antibody, showed that more than half of the participants achieved complete clearance of pustules with a single dose of the drug within a week [2]. Imsidolimab is another anti-IL-36 recept...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on